 Sanofi Pasteur, vaccine unit of Sanofi SA NASDAQ: SNY and Translate Bio Inc NASDAQ: TBIO have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The 280-subject trial will assess the safety and immunogenicity immune response of the monovalent single-strain mRNA-based flu vaccine candidate. 